戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (left1)

通し番号をクリックするとPubMedの該当ページを表示します
1                                              POMA disease antisera (6/6) recognize the third KH domai
2 e associations with POMA balance (P = 0.02), POMA gait scores (P < 0.01), and IADL (P < 0.01).
3  paraneoplastic opsoclonus-myoclonus ataxia (POMA) antigen.
4  Paraneoplastic opsoclonus myoclonus ataxia (POMA) is a neurologic disorder thought to be mediated by
5  paraneoplastic opsoclonus myoclonus ataxia (POMA) patients with latent cancer, reduced inhibitory co
6  paraneoplastic opsoclonus myoclonus ataxia (POMA), a disorder associated with breast cancer and moto
7  paraneoplastic opsoclonus myoclonus ataxia (POMA), an autoimmune neurologic disease characterized by
8  paraneoplastic opsoclonus myoclonus ataxia (POMA), Nova-1 and Nova-2 proteins are present as auto-an
9  paraneoplastic opsoclonus-myoclonus ataxia (POMA).
10 [paraneoplastic opsoclonus-myoclonus ataxia (POMA)].
11  paraneoplastic opsoclonus-myoclonus-ataxia (POMA).
12 in vitro, and this binding can be blocked by POMA antisera.
13                                     However, POMA antisera recognize antigens that are widely express
14 l for understanding the motor dysfunction in POMA.
15 to the cause of abnormal motor inhibition in POMA.
16 m for the loss of motor function observed in POMA patients.
17 ults demonstrate that the immune response in POMA targets a family of highly related sequence-specifi
18 A may underlie the motor dysfunction seen in POMA.
19 ate with the predominantly motor symptoms in POMA.
20                  Thus, a cardinal feature of POMA is the production of antibodies that inhibit Nova-1
21                                          One POMA disease antigen, termed Nova-1, has been identified
22 A antisera to clone a cDNA encoding a second POMA disease antigen termed Nova-2.
23 he development of cognitive deficits in some POMA patients.
24                                 We have used POMA antisera to clone a cDNA encoding a second POMA dis
25 howed significant negative associations with POMA balance (P = 0.02), POMA gait scores (P < 0.01), an
26 a significant positive association only with POMA balance scores (P < 0.045).

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。